Beyond Air, Inc. (XAIR) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, Beyond Air, Inc.'s filing signal continuing negative.

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on developing a platform of nitric oxide (NO) generators and delivery systems, known as the LungFit platform. Its flagship product, LungFit PH, received FDA premarket approval in June 2022 for treating neonates with hypoxic respiratory failure associated with pulmonary hypertension and has since received European CE mark approval. The company is also exploring NO's potential in treating severe lung infections, nontuberculous mycobacteria (NTM) lung infections, and chronic obstructive pulmonary disease (COPD). Beyond its LungFit platform, Beyond Air is investigating ultra-high concentration NO for solid tumors through its majority-owned affiliate Beyond Cancer, and nNOS inhibitors for neurological conditions like autism spectrum disorder through its majority-owned affiliate NeuroNOS.

Revenue is primarily driven by the sale and lease of its LungFit PH devices to hospitals and medical facilities in the United States. The company also anticipates future revenue contributions from international partnerships and the commercialization of its other product candidates.